NeoGenomics, Inc. (NEO:NASDAQ) closed at $16.80 on October 26, 2026, up 1.27% on the day. The stock trades 16.6% below its 52-week high of $20.15 and 137.6% above its 52-week low of $7.07. Over the past year, it gained 55.5%. NeoGenomics, Inc. is part of the Health Care sector (Precision Instruments).
In 252 trading sessions since October 23, 2025, NEO closed higher on 135 days (54%). Its best day was July 29, 2026 (+13.96%) and its worst was October 6, 2026 (-13.70%). The stock moved 10% or more in a single session 5 times. It opened at least 5% above the previous day's high 3 times.
NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in sup...
Find more stocks like NEO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.